SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
biotech firesales
An SI Board Since August 2001
Posts SubjectMarks Bans
3661 167 0
Emcee:  dalroi Type:  Moderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3136Bluebird Bio (BLUE), which had fireworked a week ago on anticipation of data to tuck-5/21/2014
3135XOMA 18% on earnings.nigel bates-5/9/2014
3134CORT -50% 8:34 am Corcept Therapeutics reports interim analysis of data from Phatnsaf-5/7/2014
3133Bought 10k ECYT at 6.79El Canadiense-5/5/2014
3132I never followed this company much, but I went and looked at their pipeline and tuck-5/3/2014
3131Interesting comments on Yahoo ECYT board...this might be far from over and the sEl Canadiense-5/3/2014
3130PCYC down 11% When it should have been up 5%. Does that count as over 15%? ;-IRWIN JAMES FRANKEL-5/2/2014
3129EndoCyte (ECYT) off 60% again as subset analysis apparently didn't work, evetuck-5/2/2014
3128OGXI and ATHX look to be cut in half this morning on their respective trial failnigel bates-4/28/2014
3127CytoKinetics (CYTK) off 60% as ALS drug misses primary endpoint. Not sure I'tuck-4/25/2014
3126TGTX -14% (was -15%) on no company-specific news I know of: siliconinvestor.comDewDiligence_on_SI-4/15/2014
3125Retrophin (RTRX), which had been on quite the tear over the past year, is off 15tuck-4/14/2014
3124StemCells (SCTPF) off 15% on no recent news. It does lack some near term catalytuck-4/14/2014
3123RGDO -18% on bad financing: siliconinvestor.comDewDiligence_on_SI-4/11/2014
3122HALO -25% SAN DIEGO, April 4, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (tnsaf-4/4/2014
3121MNTA -12% (was briefly -15%) on USSC’s granting certiorari for Copaxone patent cDewDiligence_on_SI-3/31/2014
3120PRAN off 70% to 2.86 on 6X daily volume on news of Alz Phase 2 failure. AF bpgo-neil-3/31/2014
3119Exelixis' (EXEL) COMET-1 trial given the green light to keep going by DSMB, tuck-3/26/2014
3118StemCell Therapeutics (SCTPF) is off almost 18% today on no news, and slightly htuck-3/19/2014
3117GERN down 66 percent on clinical hold. Tough news, I was very optimistic about fred hayes-3/12/2014
3116SSH -22%, apparently the slow pace of enrolment in their trial is a worry.tnsaf-3/11/2014
3115NLNK -16% after interim-analysis result thestreet.comtnsaf-3/7/2014
3114...my impression is that the value here is in the eye programs. The osteoarthrDewDiligence_on_SI13/5/2014
3113Interesting that it's down almost 25 percent. Followed this for awhile and fred hayes-3/5/2014
3112XOMA 24% on last night's news about gevokizumab in osteoarthritis.nigel bates-3/5/2014
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News